26 February 2012
In America, the first drug for an advanced form of basal cell carcinoma (BCC), the most common type of skin cancer, won approval from the Food and Drug Administration (FDA). The drug, Erivedge, made by Genentech, was approved for adults with BCC that has spread elsewhere in the body or those who cannot have the surgery or radiation ordinarily used to treat the disease.
BCC is the most common form of skin cancer, accounting for 80% of all cases of skin cancers. They commonly appear as non-healing fleshy bumps (like a small pearl), nodules or red patches. Mostly they are found on the head, neck and areas exposed to sunlight. BCCs do not usually spread, but need to be treated adequately to prevent them coming back. With proper treatment there is a high cure rate, although they can return.
© Skin Care Network 2012